Provided by Tiger Trade Technology Pte. Ltd.

FOSUN PHARMA

17.370
-0.530-2.96%
Volume:4.98M
Turnover:86.67M
Market Cap:46.19B
PE:11.72
High:17.800
Open:17.800
Low:17.180
Close:17.900
52wk High:28.232
52wk Low:14.505
Shares:2.66B
HK Float Shares:540.97M
Volume Ratio:1.02
T/O Rate:0.92%
Dividend:0.46
Dividend Rate:2.62%
EPS(LYR):1.482
ROE:7.04%
ROA:1.53%
PB:0.81
PE(LYR):11.72
PS:0.94

Loading ...

BRIEF-Shanghai Fosun Pharma Announces Approval From NMPA For Clinical Trial Of FXB0871

Reuters
·
Mar 31

Shanghai Fosun Pharma - Approval From Nmpa for Clinical Trial of Fxb0871

THOMSON REUTERS
·
Mar 31

FOSUN PHARMA Reports 2025 Results: Revenue Hits 41.7B Yuan with 21.7% Net Profit Growth

Deep News
·
Mar 25

FOSUN PHARMA Shares Surge Over 5% as Annual Net Profit Climbs 21.69% to 3.37 Billion Yuan

Deep News
·
Mar 25

Stock Track | Fosun Pharma Soars 5.21% Intraday on Strong 2025 Earnings and Dividend Announcement

Stock Track
·
Mar 25

FOSUN PHARMA Declares Final Dividend of HK$0.39 Per Share

Stock News
·
Mar 25

Fosun Pharma Announces RMB0.39 Final Dividend for FY2025

Bulletin Express
·
Mar 25

Fosun Pharma 2025 Results: Net Profit Up 21.69%, Innovative-Drug Sales Surge 29.59%

Bulletin Express
·
Mar 25

Shanghai Fosun Pharma - Proposed to Distribute Cash Dividend of RMB0.39 for Each Ordinary Share

THOMSON REUTERS
·
Mar 25

Press Release: Fosun Pharma Announces 2025 Annual Results

Dow Jones
·
Mar 24

FOSUN PHARMA Subsidiaries to Expand Financing Through Leasing Agreements

Stock News
·
Mar 24

Fosun Pharma Reports 2025 Results: Dual Engines of Innovative Drugs and Globalization Drive High-Quality Growth

Stock News
·
Mar 24

Fosun Pharma (02196) Subsidiary Obtains NMPA Green Light for Sodium Thiosulfate Injection

Bulletin Express
·
Mar 20

FOSUN PHARMA Subsidiary Gains Approval for Phase I Trial of HLX18 in Solid Tumors

Stock News
·
Mar 20

FOSUN PHARMA's Sodium Thiosulfate Injection Receives Regulatory Approval

Stock News
·
Mar 20

Fosun Pharma (02196): Subsidiary MicroH Therapeutics Secures NMPA Green Light for Phase I Trial of LBP-ShC4 Live Biotherapeutic

Bulletin Express
·
Mar 16

FOSUN PHARMA's HLX07 Combined with Serplulimab Injection and Chemotherapy Cleared for Clinical Trial in Advanced Squamous Non-Small Cell Lung Cancer

Stock News
·
Mar 16

Fosun Pharmaceutical Gets Chinese Regulator's Nod for Clinical Trials of Blood Cancer Drug

MT Newswires Live
·
Mar 16

FOSUN PHARMA (02196) Subsidiary Secures NMPA Green Light for Phase I Trial of Next-Generation Bcl-2 Inhibitor FXS0683

Bulletin Express
·
Mar 13

FOSUN PHARMA Subsidiary Gains Approval for Clinical Trial of FXS0683 Tablets

Stock News
·
Mar 13